GE HealthCare FDA Device Footprint: Clearances, PMA & Recalls Guide
A data-driven regulatory profile of GE HealthCare's FDA clearances, PMA approvals, safety recalls, and offshore manufacturing hubs in India, Mexico, and Finland.
Executive Summary
What does the FDA database reveal about GE HealthCare's medical device clearance history, recalls, and manufacturing footprint?
GE HealthCare holds a major regulatory presence with 1,680 active 510(k) clearances (counting GE HealthCare entities together with its Datex-Ohmeda patient-monitoring and anesthesia business) and 95 PMA approvals or supplements. The company's 510(k) clearances are concentrated in the Radiology (1,008 clearances, or 60.0%) and Cardiovascular (298 clearances, or 17.7%) specialties, followed by Anesthesiology (186 clearances, or 11.1%) from the Datex-Ohmeda franchise, led by diagnostic ultrasound systems (product code IYN, 179 clearances), magnetic resonance imaging scanners (product code LNH, 152 clearances), and computed tomography (product code JAK, 138 clearances). In the high-risk PMA sector, GE's portfolio is focused on breast oncology diagnostics, led by digital mammography systems (product code MUE, 37 filings) and automated breast ultrasound systems (product code PAA, 12 filings).
This large footprint is accompanied by 1,490 FDA-registered recalls, with MRI scanners (product code LNH, 208 recalls) and CT scanners (product code JAK, 146 recalls) representing the highest recall frequencies. Geographically, GE HealthCare operates a highly globalized manufacturing footprint, with leading registered manufacturing hubs located in Bangalore, India (624 listings), Juarez, Mexico (555 listings), and Helsinki, Finland (464 listings).
GE HealthCare FDA Footprint at a Glance
- 510(k) clearances: 1,680 (Radiology 1,008 / Cardiovascular 298 / Anesthesiology 186)
- PMA approvals and supplements: 95 (led by mammography MUE — 37)
- FDA-registered recalls: 1,490 (led by MRI LNH — 208, CT JAK — 146)
- Establishment / device listings: 5,512 (Bangalore, Juarez, Helsinki lead)
- Cumulative FDA AI/ML authorizations: ~120 at end-2025 — the most of any OEM
- Defining 2026 event: June 2026 Class I correction of Giraffe and Panda infant resuscitation blenders
Introduction: The Independent Footprint of GE HealthCare
GE HealthCare operates as an independent, publicly traded corporation following its high-profile spin-off from General Electric in January 2023. As a standalone entity, the company is structured into four core segments: Imaging (magnetic resonance, computed tomography, molecular imaging, and X-ray systems), Ultrasound (radiology, cardiology, women's health, and point-of-care systems), Patient Care Solutions (monitoring, anesthesia, maternal-infant care, and cardiology diagnostics), and Pharmaceutical Diagnostics (contrast media and molecular imaging agents). Independence has sharpened GE HealthCare's capital-allocation focus on AI-enabled imaging and digital health, which is now the fastest-growing part of its regulatory pipeline.
For healthcare buyers, regulatory managers, and operations teams, GE HealthCare represents one of the primary original equipment manufacturers (OEMs) in clinical medicine. Its installed base is massive: its technologies are used in millions of medical procedures worldwide every day. However, managing vendor risk and maintaining quality systems compliance requires a thorough evaluation of the company's FDA registry profiles.
This report analyzes GE HealthCare's active 510(k) clearances, Premarket Approval (PMA) history, product recalls, and international manufacturing registrations. Using computed aggregates from the official FDA databases, we detail the specific product codes, clinical trends, and global supply chain sites that shape GE HealthCare's regulatory profile.
How These Numbers Were Computed
The figures in this dossier are aggregates computed from four public FDA datasets extracted in June 2026: the 510(k) database, the PMA database, the medical device recalls database, and the Establishment Registration and Device Listing database. Counts are produced by grouping records under each company's brand and its registered medical-device subsidiaries — for GE HealthCare this includes the Datex-Ohmeda patient-monitoring and anesthesia business that operates under the GE HealthCare umbrella. Because legacy submissions often retain their original applicant name (for example, historical Datex-Ohmeda 510(k)s), clearances are counted across those entity names, while current establishment listings are attributed to the operating GE HealthCare facilities that hold them today. Raw recall counts are reported as filed and should always be read against installed base: a company with a larger fleet of complex capital equipment will generate more field corrections than a niche manufacturer, so a high recall count is not by itself a quality verdict. This methodology is the same one applied across our peer company profiles so the numbers are directly comparable.
The 510(k) Clearance Portfolio: Ultrasound and Imaging Leadership
The 510(k) pathway is the primary method for GE HealthCare to clear diagnostic systems, patient monitors, and clinical software for commercial distribution in the United States.
As of June 2026, GE HealthCare holds 1,680 active 510(k) clearances (GE HealthCare entities plus the Datex-Ohmeda monitoring and anesthesia business). Segmenting these clearances by FDA medical specialty reveals a portfolio weighted toward diagnostic imaging but with a substantial anesthesia and monitoring block:
| Medical Specialty | Clearance Count | Percentage of 510(k) Portfolio | Core Technologies |
|---|---|---|---|
| Radiology | 1,008 | 60.0% | Computed Tomography (CT), MRI, Diagnostic Ultrasound, X-Ray, PACS |
| Cardiovascular | 298 | 17.7% | Cardiac Ultrasound (Echocardiography), ECG systems, cath lab monitors |
| Anesthesiology | 186 | 11.1% | Anesthesia workstations (Carestation, Datex-Ohmeda), respiratory accessories |
| General Hospital | 68 | 4.0% | Infant warmers, phototherapy lights, patient monitors |
| Obstetrics/Gynecology | 50 | 3.0% | Voluson OB/GYN ultrasound platforms, fetal monitors |
| Other Specialties | 70 | 4.2% | Dental, neurology, gastroenterology/urology, plastic surgery |
| Total Active Clearances | 1,680 | 100.0% |
Top 510(k) Product Codes and Device Families
The top five product codes within GE HealthCare's 510(k) portfolio represent their market leadership in diagnostic ultrasound, CT, and MRI systems:
- IYN (179 clearances): System, Imaging, Pulsed Doppler, Ultrasonic (21 CFR 892.1550, Class II). This represents GE's extensive diagnostic ultrasound portfolio, including the Logiq (general imaging), Vivid (cardiology), and Voluson (women's health) platform series.
- LNH (152 clearances): System, Nuclear Magnetic Resonance Imaging (21 CFR 892.1000, Class II). This code represents GE's Signa MRI scanner series, including the 1.5T Creator and Artist, 3T Pioneer and Premier, and dedicated clinical software suites.
- JAK (138 clearances): System, X-Ray, Tomography, Computed (21 CFR 892.1750, Class II). This code covers the Revolution, Optima, and LightSpeed CT scanner series, ranging from mobile systems to the high-end Revolution Apex platforms.
- LLZ (89 clearances): System, Image Processing, Radiological (21 CFR 892.2050, Class II). This covers radiological imaging software, Picture Archiving and Communication Systems (PACS), and the Centricity clinical workspace tools.
- MHX (86 clearances): Monitor, Physiological, Patient (With Arrhythmia Detection or Alarms) (21 CFR 870.1025, Class II). This code represents GE's physiological patient monitoring platforms — including the Dash, Solar, and CARESCAPE monitor families used across ward, ICU, and procedural monitoring.
GE HealthCare Top 510(k) Product Codes:
IYN (Ultrasonic Imaging): [===================================] 179
LNH (Magnetic Resonance): [==============================] 152
JAK (Computed Tomography): [===========================] 138
LLZ (Radiological Software): [=================] 89
MHX (Patient Monitoring): [=================] 86
Annual Clearance Trends (2020–2026)
Tracking GE HealthCare's annual clearance counts shows a stable R&D output, with a slight post-spin-off realignment in 2024–2025:
| Year | Clearance Volume | Key Product Clearances & Strategic Context |
|---|---|---|
| 2020 | 37 | High clearance of maternal-fetal monitoring software and portable ultrasound consoles during the pandemic. |
| 2021 | 27 | Focus on integrated analytics suites and Signa MRI hardware modifications. |
| 2022 | 38 | Clearance of next-gen Revolution CT software and expanded echo ultrasound software parameters. |
| 2023 | 29 | First post-spin-off year; focus on AI-assisted patient positioning CT gantry tools and Vscan Air handheld models. |
| 2024 | 22 | Introduction of Genesis Workspace radiology diagnostics, MIM oncology auto-contouring systems, and advanced interventional C-arms. |
| 2025 | 27 | Gaining clearances for Allia Moveo interventional systems and cloud-native viewer platforms. |
| 2026 (Part) | 15 | Mid-year run-rate; includes MIM Contour ProtégéAI+ 2.0 software with a Predetermined Change Control Plan. |
GE's Lead in AI-Enabled Clearances
A key trend in GE HealthCare's regulatory strategy is the integration of artificial intelligence and machine learning (AI/ML) into its cleared systems. GE HealthCare has topped the FDA's public list of AI/ML-enabled medical device authorizations for four consecutive years, reporting roughly 100 listed authorizations in the U.S. by mid-2025 and an estimated 120 cumulative authorizations by the end of 2025 — ahead of other imaging OEMs — with a stated goal of exceeding 200 authorizations by 2028.
These authorizations include tools like Sonic DL (an AI-powered MRI reconstruction software that GE reports can shorten scan times substantially), Auto-Contouring oncology tools, and Effortless Workflow packages for CT systems. The company has actively utilized the FDA's Predetermined Change Control Plan (PCCP) framework to allow these AI models to iteratively improve in the clinic without requiring repeated 510(k) submissions.
Premarket Approval (PMA) Portfolio: Focus on Breast Care
While GE HealthCare's PMA portfolio of 95 approvals and supplements is smaller than its imaging 510(k) library, it contains critical, high-risk clinical technologies. Unlike competitors whose PMAs focus on implantable cardiovascular hardware, GE HealthCare's PMA footprint is heavily concentrated in women's health, specifically breast cancer screening and diagnostic technologies.
The top product codes in GE's PMA portfolio are:
- MUE (37 filings): Full Field Digital System, X-Ray, Mammographic (21 CFR 892.1715, Class III). This code represents GE's Senographe mammography platforms. Because digital mammography systems serve as a primary screening tool for asymptomatic populations, they were historically regulated under the PMA pathway to ensure high image quality and controlled radiation dosage.
- LNH (19 filings): Computed Tomography or MRI features that support high-risk clinical indications (such as specific MR spectroscopy or high-field imaging sequences cleared under the PMA pathway).
- PAA (12 filings): Automated Breast Ultrasound (21 CFR 892.1560, Class III). This code covers the Invenia Automated Breast Ultrasound System (ABUS), cleared as an adjunct to mammography for breast cancer screening in women with dense breast tissue.
- MCP (12 filings): Stimulator, Fetal, Acoustic (21 CFR 884.2700, Class III). Acoustic stimulators used in maternal care to assess fetal heart rate reactivity during non-stress testing.
- OTE (6 filings): Digital Breast Tomosynthesis (21 CFR 892.1715, Class III). Covers 3D mammography platforms that help reduce false positives and improve cancer detection rates in dense breasts.
The clinical and regulatory requirements for maintaining these PMAs involve rigorous post-market surveillance. Any changes to the mammography detectors, tube assemblies, or automated image acquisition algorithms require formal PMA supplements, ensuring that modifications do not impact the diagnostic sensitivity of the screening tools.
FDA Recalls and Safety Signals: Trends and Root Causes
Managing safety alerts is a key component of vendor evaluation for clinical engineering and hospital risk departments. As of June 2026, FDA records associate 1,490 medical device recalls with GE HealthCare.
As with Siemens, these recall figures must be analyzed relative to GE's massive market footprint. A large installed base naturally generates more field corrections and safety alerts.
Annual Recall Trends (2020–2026)
Analyzing the year of initiation for GE HealthCare's recall records highlights the impact of corporate scaling and regulatory compliance monitoring:
| Year | Recall Volume | Core Product Lines Affected | Strategic Context & Regulatory Rationale |
|---|---|---|---|
| 2020 | 41 | Diagnostic CT systems, ultrasound probes | Software gantry errors, scanner component failures, mechanical stability adjustments. |
| 2021 | 87 | Carestation Anesthesia Systems, Patient monitors | Ventilator software bugs, electrical noise interference, cable harness faults. |
| 2022 | 45 | Signa MRI systems, X-Ray tube components | RF coil heat monitoring faults, CT collimator alignment defects. |
| 2023 | 47 | syngo software (select applications), diagnostic PACS | Software image transfer delays, server-side interface connectivity faults. |
| 2024 | 113 | Revolution CT platforms, telemetry monitoring | Spiked recall volume; software patches for CT server security, central station dropouts. |
| 2025 | 109 | Omni Legend PET systems, MRI cryogen vents | Software streaking artifacts, venting system pressure valve adjustments. |
| 2026 (Part) | 26 | Giraffe/Panda resuscitator systems, CT Workstations | Resuscitation blender knob loosening, C-arm mechanical calibration faults. |
This timeline reveals a significant increase in safety notifications in 2024–2025, driven by cybersecurity patches and software corrections.
Recall Distribution by Product Code
An analysis of GE's recall registrations by product code reveals that imaging capital equipment represents the highest frequency of recalls:
| Rank | Product Code | Device Category | Number of Recalls | Primary Recall Root Causes |
|---|---|---|---|---|
| 1 | LNH | Magnetic Resonance Imaging (MRI) | 208 | Superconducting magnet venting issues, helium pressure limits, RF coil heating |
| 2 | JAK | Computed Tomography (CT) | 146 | Software reconstruction anomalies, gantry software bugs, calibration drift |
| 3 | KPS | Computed Emission Tomography (PET/SPECT) | 130 | Detector assembly faults, positioning software bugs, QA software errors |
| 4 | LLZ | Radiological Image Processing Software | 129 | Imaging display delays, PACS transmission packet loss, software bugs |
| 5 | BSZ | Anesthesia Gas Machine (Datex-Ohmeda/Carestation) | 89 | Ventilator software faults, gas-delivery module calibration, valve errors |
Recent Safety Corrections (2025–2026)
Key recent safety events show how GE HealthCare manages safety alerts in the field:
- Class I Infant Blender Recall (June 2026): The FDA designated a corrective action for certain Giraffe and Panda infant resuscitation systems and warmers as a Class I recall. The recall involved systems equipped with a specific oxygen-air blender (model M1091607-R). The blender knob shaft could loosen over time, leading to an incorrect concentration of oxygen being delivered to the infant. GE HealthCare issued urgent inspection guidelines and provided replacement blender modules to affected clinical sites.
- Class II ApexPro Telemetry Server Software Correction (April 2026): GE HealthCare corrected a software bug in its ApexPro CARESCAPE telemetry servers. The software issue could lead to a persistent, undetected loss of communication between the patient's transmitter and the central station, potentially dropping ECG and SpO2 monitoring. This was resolved via a server-side software patch, illustrating the shift toward digital software corrections in patient care monitoring.
- Class II CT Server Vulnerability (May 2026): A cybersecurity vulnerability was identified in the servers supporting Revolution Apex, Revolution Ascend, and select CT systems. GE HealthCare deployed a software security update to patch the operating systems of the central workstations, preventing potential unauthorized access without impacting clinical operations.
Global Supply Chain and Facility Analysis
The geography of GE HealthCare's manufacturing network is mapped in the FDA's Establishment Registration database. Registered facilities are subject to FDA inspection and must list the devices they process for the U.S. market.
GE HealthCare holds 5,512 active establishment registration and device listings across its registered entities. This is the largest establishment footprint of the three major imaging OEMs and reflects both GE HealthCare's breadth (imaging, ultrasound, monitoring, anesthesia, and contrast media) and its distributed manufacturing model.
Our analysis of the geographic hubs in GE's FDA listings reveals a highly globalized supply chain:
| Location | Active Listings | Primary Product Focus | Supply Chain Significance |
|---|---|---|---|
| Bangalore, India | 624 | Ultrasound Probes, Monitoring Components, Software | GE's largest global facility by listing count; acts as a primary engineering and manufacturing hub for value-tier imaging and digital health. |
| Juarez, Mexico | 555 | Maternal-Infant Care, Patient Monitors, Cabling | Major nearshore manufacturing facility supplying maternal-infant care systems and patient monitoring hardware to the U.S. market. |
| Helsinki, Finland | 464 | Patient Monitors, Anesthesia Gas Modules | GE's European center of excellence for clinical monitoring, stemming from its acquisition of Datex-Ohmeda. |
| Wuxi, China | 460 | Ultrasound Systems, General Imaging Hardware | Strategic manufacturing hub for high-volume ultrasound platforms (Logiq and Voluson series) and diagnostic consoles. |
| Hino-shi, Japan | 333 | MRI Superconducting Magnets, CT Subsystems | Home of GE Healthcare Japan; manufactures high-field MR magnets and computed tomography subsystems. |
This geographic breakdown reveals that while GE HealthCare's corporate headquarters is located in Chicago, Illinois, its manufacturing operations are highly distributed. The high volume of listings in Bangalore (624) and Juarez (555) shows a strong reliance on offshore and nearshore hubs for manufacturing ultrasound systems, cables, patient monitors, and neonatal hardware.
Regulatory and Quality System Management Across International Facilities
Operating a distributed supply chain of this scale requires strict alignment under global quality standards. GE HealthCare utilizes the Medical Device Single Audit Program (MDSAP) to satisfy the regulatory requirements of multiple jurisdictions (including the FDA, Health Canada, Brazil's ANVISA, and Australia's TGA) through a single QMS audit.
Each key international hub is optimized for specific regulatory and clinical niches:
- The Indian Hub (Bangalore): Focuses heavily on ISO 13485 compliance for diagnostic ultrasound transducers and patient care software. As software-as-a-medical-device (SaMD) becomes a core component of GE's offering, the software development teams in Bangalore operate under strict IEC 62304 software lifecycle standards to manage code verification, risk assessment, and cybersecurity patch development.
- The Mexican Hub (Juarez): Operates under nearshore logistics advantages, serving as the primary assembly site for capital monitors and neonatal resuscitation hardware. This facility is subject to regular FDA inspections to verify compliance with 21 CFR Part 820 (Quality System Regulation).
- The Finnish Hub (Helsinki): Acts as the engineering center for clinical gas monitoring modules and anesthesia machines. Because European facilities must comply with both FDA QSR and the EU Medical Device Regulation (EU MDR 2017/745), the Helsinki site manages dual quality certifications, coordinating with European Notified Bodies for CE-mark maintenance.
This distribution highlights the complexity of vendor audits. Hospital procurement teams must verify that the specific facility manufacturing their equipment has a clean FDA inspection history and holds active MDSAP certifications.
Risk Management Framework for Healthcare Procurement
When managing a fleet of GE HealthCare systems, hospital procurement, clinical engineering, and risk management teams should implement a structured assessment workflow to evaluate and mitigate regulatory risks. The workflow below turns the footprint data above into concrete contract and maintenance decisions rather than abstract vendor scores.
+-----------------------------+
| Identify Product Code |
| (e.g., IYN, JAK, LNH) |
+--------------+--------------+
|
v
+-----------------------------+
| Check Manufacturing Site |
| - Is it Bangalore / Juarez |
| or a domestic plant? |
+--------------+--------------+
|
v
+-----------------------------+
| Assess Safety Alert Type |
| - Is it a software patch? |
| - Is it a physical swap? |
+--------------+--------------+
|
v
+-----------------------------+
| Implement QA SLA Check |
| - Track software updates |
| - Audit blender torque |
+-----------------------------+
1. Audit Supply Chain Origin
When purchasing GE systems, identify the specific country of origin and manufacturing site. For equipment manufactured in Bangalore, Wuxi, or Juarez, ensure that your logistics team has established contingency plans for potential import delays or shipping disruptions, and verify that the local distributor has adequate spare parts inventory in the U.S. Document the registered FEI number for the specific facility so that any future FDA inspection or import hold can be traced to the correct site.
2. Monitor Software Security Patches
Because GE HealthCare is a market leader in connected telemetry, monitoring, and AI-enabled imaging systems, its devices are highly integrated into hospital networks. Risk managers should:
- Ensure that all GE central monitoring servers (such as CARESCAPE) are placed on segregated VLANs to prevent unauthorized network access.
- Require the vendor to provide a Software Bill of Materials (SBOM) for all software-enabled devices to facilitate vulnerability management.
- Establish a regular audit cycle to confirm that cybersecurity patches (such as the May 2026 CT server patch) are applied.
- Require documented evidence of patch installation before returning a corrected system to clinical use, so that remediation is verifiable rather than assumed.
3. Establish QA Inspection Protocols for Clinical Engineering
For clinical engineering teams managing maternal-infant care systems or telemetry servers, establish specific preventative maintenance (PM) checklists:
- For Giraffe and Panda Warmers: Audit the torque and stability of the oxygen-blender knobs during annual preventative maintenance to prevent loosening.
- For Telemetry Systems: Implement central monitor loss-of-signal alerts to immediately notify clinical staff of transmitter-to-server dropouts.
How GE HealthCare Compares With Siemens Healthineers and Philips
GE HealthCare's regulatory footprint is best understood alongside its two largest imaging-OEM peers. Using the same FDA database methodology, the three companies divide the high-end capital-equipment market along distinct clinical lines:
| Regulatory Metric | GE HealthCare | Siemens Healthineers | Philips |
|---|---|---|---|
| Active 510(k) clearances | 1,680 | 1,573 | 1,322 |
| PMA approvals / supplements | 95 | 540 | 350 |
| FDA-registered recalls | 1,490 | 2,042 | 2,397 |
| Establishment / device listings | 5,512 | 4,114 | 5,180 |
| Leading 510(k) product code | IYN — ultrasound (179) | JAK — CT (155) | LNH — MRI (125) |
| PMA portfolio focus | Breast / mammography (MUE, 37) | In-vitro diagnostics (LOM, 189) | Cardiovascular interventions (LPC, 124) |
| Cumulative AI authorizations (end-2025) | ~120 (leads the FDA list) | ~89 | ~50 |
Three observations stand out for procurement and regulatory teams. First, GE HealthCare runs the smallest PMA book of the three because its highest-risk devices are concentrated in a narrow breast-imaging line rather than implantable therapeutics or IVD assays; Siemens' 540 PMAs are dominated by laboratory diagnostics and Philips' 350 by cath-lab and defibrillation devices. Second, GE HealthCare has the most distributed manufacturing footprint by listing count (5,512), with a heavier reliance on offshore hubs in India and Mexico than its European peers. Third, GE HealthCare leads on cumulative FDA AI/ML authorizations, which is relevant for hospitals standardizing on AI-enabled imaging workflows. For a cross-manufacturer view of where recall burden concentrates across the industry, see our FDA medical device recall manufacturer concentration analysis; for GE HealthCare's corporate and pricing strategy, see our GE HealthCare 2026 restructuring guide, and for the AI framework GE relies on, see our FDA Predetermined Change Control Plan (PCCP) guide.
Common Pitfalls When Auditing a GE HealthCare Footprint
Vendor audits of large OEMs fail in predictable ways. Avoid these recurring mistakes:
- Judging the company as one entity. GE HealthCare's imaging, ultrasound, and patient-care businesses operate on separate quality systems and in different facilities. A software recall on a CT server does not predict the behavior of a Giraffe infant warmer manufactured in Juarez. Scope every audit to the product code and the specific registered facility.
- Ignoring the offshore manufacturing dependency. With Bangalore (624 listings) and Juarez (555 listings) as the largest hubs, logistics teams should pre-qualify alternate import pathways and confirm U.S. spare-parts stocking levels before signing a capital contract, especially for maternal-infant and monitoring hardware.
- Treating recall volume as a safety grade. GE's ~1,490 recalls are dominated by Class II software corrections on a very large installed base. The operationally meaningful signal is the response time for Class I corrections (such as the June 2026 infant blender action), not the gross count.
- Overlooking cybersecurity as a post-market obligation. Because GE's capital equipment is networked (CARESCAPE telemetry, CT servers, AI viewers), a procurement SLA that ignores patch deployment cadence will understate real operational risk.
What the Footprint Numbers Mean for Your Risk Model
A regulatory footprint is only useful if it changes a decision. For GE HealthCare, three quantitative signals translate directly into procurement and risk-management action:
- PMA concentration signals the critical spares list. With mammography (MUE) and automated breast ultrasound (PAA) as the dominant PMA codes, a breast-imaging center should treat detector and tube-assembly service parts as single-vendor critical spares, because PMA supplements for any change to those components take far longer than a 510(k). Build replacement-part inventory accordingly.
- The 510(k) specialty mix signals training and integration load. Because GE HealthCare's clearances are weighted to ultrasound, CT, and MRI (plus a large anesthesia block from Datex-Ohmeda), standardizing on GE across a department concentrates integration and training on one vendor — a real efficiency, but it also concentrates cybersecurity and patch-management risk on a single supplier's release cadence.
- Recall trend inflection points signal when to escalate. GE's recall volume rose sharply in 2024 (113) and 2025 (109), driven largely by software and cybersecurity corrections on networked systems. A risk committee that reviews recall trends annually should treat a sustained jump like this as a trigger to renegotiate patch-deployment SLAs and to review network segmentation for connected devices, not merely as a number to log.
The practical test is whether the footprint changes how you write the contract. If your GE HealthCare capital agreement does not specify Class I recall notification latency, software-patch deployment windows, cybersecurity SBOM delivery, and the offshore-facility continuity plan, the data above has not yet been put to work.
What is the most common medical specialty for GE HealthCare's FDA clearances?
Radiology is the dominant specialty, representing 60.0% (1,008 clearances) of GE's 1,680 active 510(k) clearances. Cardiovascular devices represent the second largest category with 17.7% (298 clearances), followed by Anesthesiology with 11.1% (186 clearances) driven by the Datex-Ohmeda monitoring and anesthesia franchise.
Why does product code IYN represent the highest clearance count for GE?
Product code IYN stands for System, Imaging, Pulsed Doppler, Ultrasonic (21 CFR 892.1550, Class II). It represents GE HealthCare's diagnostic ultrasound portfolio (Logiq, Vivid, Voluson), which is a key commercial driver for the company.
Where are GE HealthCare's primary manufacturing facilities located?
GE's primary manufacturing and listing hubs are located in Bangalore, India (624 listings for ultrasound and software), Juarez, Mexico (555 listings for monitors and maternal-infant care), and Helsinki, Finland (464 listings for patient monitors and clinical modules).
How does GE HealthCare manage AI software updates without requiring new clearances?
GE HealthCare utilizes the FDA's Predetermined Change Control Plan (PCCP) framework. This allows the company to outline planned AI model updates in the initial submission, enabling the software to improve and update in the clinic without requiring a new 510(k).
Why is GE HealthCare's PMA portfolio so much smaller than Siemens' or Philips'?
GE HealthCare's 95 PMAs are concentrated in breast imaging (digital mammography under MUE and automated breast ultrasound under PAA). Siemens and Philips each hold far more PMAs because their highest-risk businesses sit elsewhere — Siemens in laboratory IVD assays (hepatitis, PSA, AFP) and Philips in cardiovascular interventional devices (laser angioplasty, lead extraction, defibrillation). A small PMA count is not a weakness; it reflects where each company chose to compete in Class III.
How should a hospital weigh GE HealthCare's recall count when selecting a vendor?
Use recall counts as a denominator-aware signal, not a ranking. GE HealthCare's ~1,490 recalls are concentrated in imaging capital equipment (MRI, CT, PET) and anesthesia systems on a very large installed base, and the majority are Class II software corrections resolved remotely. The audit-relevant questions are the vendor's notification latency for Class I actions, the on-site remediation timeline, and whether downtime from corrections is excluded from the clinical uptime SLA.
Does the Datex-Ohmeda acquisition still show up in GE HealthCare's FDA footprint?
Yes. Datex-Ohmeda's anesthesia and patient-monitoring products remain a meaningful part of GE HealthCare's 510(k) clearances (notably the BSZ anesthesia gas-machine code and MHX patient-monitor code) and its Helsinki and Madison-area manufacturing footprint. Legacy submissions retained the Datex-Ohmeda applicant name, so a complete footprint count must include those entity names.
How does GE HealthCare's offshore manufacturing concentration affect supply continuity?
With Bangalore (624 listings) and Juarez (555 listings) as the two largest hubs, a meaningful share of GE HealthCare's patient-monitoring, maternal-infant, and ultrasound hardware is produced outside the United States. That lowers unit cost but exposes hospitals to import-logistics and tariff risk; procurement teams should confirm U.S. spare-parts stocking and alternate-sourcing plans in the service agreement.
Bottom Line for Procurement and Regulatory Teams
GE HealthCare's FDA footprint describes a focused, imaging-led OEM with a strong AI authorization lead, a relatively small but clinically important PMA book in breast care, and a highly distributed offshore-leaning manufacturing base. For a hospital or GPO, the actionable conclusions are concrete: standardize cybersecurity and patch SLAs around the networked imaging and monitoring estate, treat the mammography and ABUS PMA lines as single-vendor critical spares, plan maternal-infant and monitor continuity against the Bangalore and Juarez hubs, and audit recalls at the product-code and facility level rather than the corporate level. Used this way, the regulatory database is not a trivia sheet — it is a vendor-risk instrument that should directly shape the language of the capital contract.
Sources
- FDA Medical Device Databases: U.S. Food and Drug Administration. Access data source for 510(k), Premarket Approval, and Recall registries. FDA Medical Device Databases
- GE HealthCare Documentation & Support Library: Technical manuals, service bulletins, and safety notices database. GE HealthCare Support
- FDA Establishment Registration and Device Listing Database: Registry of active medical device manufacturers and listed devices. FDA Establishment Registration
- FDA Class I Recall Database: Safety alerts and recall details for critical medical device corrections. FDA Recalls Database
- MIM Software Product Documentation: Product specifications and clearances for MIM radiation planning tools. MIM Software
Disclaimer: This analysis is based on the June 10, 2026 extracts of the FDA 510(k), PMA, Recalls, and Establishment Registration databases, alongside public announcements from the 2025–2026 period. It is intended for educational and market research purposes only and does not constitute legal, regulatory, or clinical advice for any specific product, institution, or clinical application.